Plural Nitrogens Nonionically Bonded Patents (Class 514/564)
-
Publication number: 20130035390Abstract: Disclosed are methods for treating multiple sclerosis patients that entail co-administration of effective amounts of a Ras antagonist which is farnesylthiosalicylic acid or an analog thereof, and a second active agent selected from glatiramer acetate, laquinimod and combinations thereof. Therapeutic compositions and methods of making them are also disclosed.Type: ApplicationFiled: January 13, 2011Publication date: February 7, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Elizabeta Aizman, Joab Chapman
-
Publication number: 20130030054Abstract: An object of the present invention is to provide an ornithine-containing alcohol-free malt beverage which is provided with health functions of ornithine imparted to an alcoholic beverage-flavored alcohol-free malt beverage containing substantially no alcohol component and which retains an excellent flavor of the alcohol-free malt beverage, and to provide a method for producing the same. The ornithine-containing alcohol-free malt beverage of the present invention is produced using ornithine hydrochloride and ornithine aspartate in combination as ornithine raw materials. For this production, 20% or more by weight of ornithine hydrochloride in terms of ornithine is used with respect to the total weight of ornithine hydrochloride and ornithine aspartate in terms of ornithine. The ornithine-containing alcohol-free malt beverage thus produced is provided with health functions of ornithine and retains an excellent flavor of an alcohol-free malt beverage. In this way, the object can be attained.Type: ApplicationFiled: December 28, 2010Publication date: January 31, 2013Applicants: KIRIN HOLDINGS KABUSHIKI KAISHA, KIRIN BEER KABUSHIKI KAISHA, KYOWA HAKKO BIO CO., LTD., KOIWAI DAIRY PRODUCTS CO., LTD., KIRIN BEVERAGE COMPANY, LIMITEDInventors: Yukimasa Owa, Takehito Ota, Kinya Kurihara
-
Patent number: 8362044Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: GrantFiled: October 12, 2011Date of Patent: January 29, 2013Assignee: Panmira Pharmaceuticals, LLCInventors: John Howard Hutchinson, Brian Andrew Stearns, Jill Melissa Scott, Yen Pham Truong, Jeffrey Roger Roppe, Nicholas Simon Stock, Jeannie M. Arruda, Thomas Jon Seiders, Bowei Wang, Deborah Volkots
-
Publication number: 20130023463Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.Type: ApplicationFiled: April 19, 2012Publication date: January 24, 2013Applicant: ABBOTT LABORATORIESInventors: Charles A. Flentge, Hui-Ju Chen, David A. DeGoey, William J. Flosi, David J. Grampovnik, Peggy P. Huang, Dale J. Kempf, Larry L. Klein, Allan C. Krueger, Darold L. Madigan, John T. Randolph, Minghua Sun, Ming C. Yeung, Chen Zhao
-
Publication number: 20130018080Abstract: A composition comprising leucine, isoleucine, valine, threonine and lysine for treating chronic obstructive pulmonary disease.Type: ApplicationFiled: November 26, 2010Publication date: January 17, 2013Inventors: Francesco Saverio Dioguardi, Isabella Arborio Mella, Edoardo Carlo Maria Conti, Giovanni Federico Maria Conti
-
Patent number: 8344177Abstract: The invention relates to portable albumin binders, which are useful for improving the pharmacokinetic properties of diagnostic or therapeutic agents, in particular increasing the blood circulations time and/or the tissue penetration capacity of such agents.Type: GrantFiled: November 2, 2007Date of Patent: January 1, 2013Assignee: Philochem AGInventors: Dario Neri, Christoph Dumelln
-
Publication number: 20120329846Abstract: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-?. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-? production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.Type: ApplicationFiled: March 27, 2012Publication date: December 27, 2012Applicant: Ajinomoto Co., Inc.Inventors: Hideki Matsumoto, Tomohisa Okutsu, Tomoko Takeda, Hideki Suzuki, Tetsuo Yano, Masaki Hashimoto, Miho Ono, Manabu Suzuki
-
Patent number: 8338484Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: GrantFiled: November 15, 2011Date of Patent: December 25, 2012Assignee: Panmira Pharmaceuticals, LLCInventors: John Howard Hutchinson, Brian Andrew Stearns, Yen Pham Truong
-
Publication number: 20120316171Abstract: Methods and compositions for the treatment and/or management of cancer are disclosed, which comprise the use of tryptophan hydroxylase inhibitors.Type: ApplicationFiled: November 4, 2010Publication date: December 13, 2012Inventor: Tamas Oravecz
-
Publication number: 20120315283Abstract: Described herein are methods of using soluble epoxide hydrolase inhibitors to modulate the levels of epoxyeicosatrienoic acids (EETs) in order to increase angiogenesis and promote wound healing and tissue regeneration.Type: ApplicationFiled: February 1, 2011Publication date: December 13, 2012Applicants: DANA-FARBER CANCER INSTITUTE, INC., CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Dipak Panigraphy, Mark Kieran
-
Publication number: 20120315281Abstract: Methods for the treatment of renal injury include the use of arginase inhibitors in the treatment and prevention of diabetic nephropathy, albuminuria and azotemia amongst others, and methods for identifying agents for the treatment of renal injury.Type: ApplicationFiled: May 11, 2012Publication date: December 13, 2012Applicant: THE PENN STATE RESEARCH FOUNDATIONInventor: Alaa S. AWAD
-
Publication number: 20120316215Abstract: Disclosed are methods for treating a subject suffering from phenylketonuria and/or phenylalanemia. The methods include, in part, enterally administering to the subject a LNAA supplement in which the weight ratio of Leu to Val is greater than 2:1; in which the weight ratio of Leu to iLeu is greater than 3:1; or which includes one or more LNAAs and which further includes Lys. LNAA supplements are also disclosed. Also disclosed are methods for treating a subject suffering from a condition involving a metabolic disorder involving the metabolism of a first amino acid X. The method includes enterally administering to the subject a composition which (i) is substantially free from the first amino acid X and (ii) which includes a second amino acid Y that competes with amino acid X at a gastrointestinal tract transporter.Type: ApplicationFiled: August 20, 2012Publication date: December 13, 2012Applicant: PreKUlab Ltd.Inventor: Reuben Matalon
-
Publication number: 20120289470Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 15, 2011Publication date: November 15, 2012Inventors: Mark C. HEIT, Antonio M. BENITZ, Dennis F. STEADMAN, David M. PETRICK
-
Patent number: 8309767Abstract: The invention relates to 2-aminobenzoyl-alkylamines, -alkylamides and -alkylthioamides, and their application for treatment or prevention of various physiological conditions.Type: GrantFiled: June 24, 2004Date of Patent: November 13, 2012Assignee: Neurim Pharmaceuticals (1991) Ltd.Inventors: Nava Zisapel, Moshe Laudon, Dvorah Daily
-
Publication number: 20120282172Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.Type: ApplicationFiled: May 9, 2012Publication date: November 8, 2012Applicants: Centro de Neurociencias e Biologia Celular, Universidade de CoimbraInventors: João Nuno Sereno de Almeida Moreira, Vera Lúcia Dantas Nunes Caldeira de Moura, Sérgio Paulo de Magalhães Simões, Maria da Conceição Monteiro Pedroso de Lima
-
Patent number: 8303979Abstract: The invention relates to products and methods for increasing the productivity in farming by improving the fertility of healthy farming mammals. More in particular, the invention relates to products and methods for improving the fertility of animals by reducing placental insufficiency. According to the invention, this is obtained by providing a product which is enriched in L-arginine. The arginine products of the invention may be applied to improve fertility, which may be used in improving the yield in viable offspring of an animal livestock.Type: GrantFiled: January 22, 2004Date of Patent: November 6, 2012Assignee: Nutreco Nederland B.V.Inventor: Tette van der Lende
-
Publication number: 20120277245Abstract: A method of treating cancer or inhibiting metastasis in a subject by increasing intratumoral extracellular pH is presented. The method includes administering to the subject a therapeutically effective amount of a buffer having a pKa greater than 6.1. In an advantageous embodiment the pKa of the buffer is about 7.0. Examples of buffers for increasing extracellular pH include NaHCO3, 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), cholamine chloride, N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES) and 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES). The method can further include the step of pretreating with one or more chemotherapeutic agents.Type: ApplicationFiled: May 24, 2012Publication date: November 1, 2012Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Robert J. Gillies, David L. Morse, Ariosto Siqueira Silva, Arig A. Ibrahim Hashim, Robert A. Gatenby, Gary Martinez
-
Publication number: 20120277223Abstract: The present invention relates to compounds of formula (I): wherein Q, G1, G2, and G3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.Type: ApplicationFiled: July 16, 2012Publication date: November 1, 2012Inventors: Andrew S. Judd, Mathew M. Mulhern, Rajesh R. lyengar, Philip R. Kym, Andrew J. Souers
-
Publication number: 20120259016Abstract: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.Type: ApplicationFiled: June 13, 2012Publication date: October 11, 2012Applicant: UCL Business PLCInventors: Rajiv Jalan, Kamal Nayan Jalan
-
Patent number: 8282952Abstract: The invention relates to insect attractants containing compounds with pentagonal heterocyclic structures that are effective in attracting fruitflies.Type: GrantFiled: March 11, 2008Date of Patent: October 9, 2012Assignee: Activetrad (Proprietary) LimitedInventor: Christoffel J. Smit
-
Publication number: 20120252895Abstract: Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.Type: ApplicationFiled: April 25, 2012Publication date: October 4, 2012Inventors: Marshall L. Summar, Brian W. Christman, Frederick E. Barr
-
Publication number: 20120252896Abstract: The present invention provides methods for the modulation of T cells and T cell responses, particularly of Th17 effector cells. The invention provides methods of and compositions for modulating T cells, particularly T cells expressing IL-17, particularly Th17 effector cells, via the tryptophan metabolism pathway, particularly using tryptophan metabolites, kynurenines and kynurenine analogs or metabolites. The invention provides assays for screening Th17 modulators and kynurenine analogs or compounds.Type: ApplicationFiled: November 19, 2010Publication date: October 4, 2012Inventors: Joel D. Ernst, Ludovic Desvignes
-
Publication number: 20120251662Abstract: The present invention is directed to methods and compositions for making dough-based bakery foods, such as bread having extended mold-free shelf-lives, using new antimicrobial powders comprising an antimicrobial agent dispersed in a carrier. The invention is also directed to methods and compositions for preparing dough-based bakery products, such as bread, having long mold-free shelf-lives, by treating the surface of the dough with the antimicrobial powder. Further, the invention is concerned with bakery products having long, mold-free and anti-staling shelf-lives.Type: ApplicationFiled: March 31, 2011Publication date: October 4, 2012Applicant: Caravan Ingredients Inc.Inventors: Jesse Stinson, GuoHua Feng
-
Publication number: 20120232120Abstract: A compound of the formula: where X is phenyl substituted at the 3, 4 and 5 positions with R1, R2 or R3 which are selected from hydrogen, chloro, lower alkyl of 1 to 5 carbons, phenoxy, phenyl, naphthyl, or phenyl (lower) alkyl where the lower alkyl group has 1-5 carbon atoms and m is 0 or 1; Y is —CONH— or —NHCONH— where the nitrogen atoms are unsubstituted or substituted with other phenoxyisobutyric acid derivatives, or the residue of a phenoxyisobutyric acid and n is 0 or 1; Z is unsubstituted phenyl when m is 1 and n is 1; when Y is 0, X is 0; Z is also substituted.Type: ApplicationFiled: March 8, 2012Publication date: September 13, 2012Inventors: IRAJ LALEZARI, JILL FABRICANT
-
Publication number: 20120231090Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.Type: ApplicationFiled: March 8, 2012Publication date: September 13, 2012Inventors: Vladimir Bajic, Mandeep Kaur
-
Publication number: 20120232127Abstract: A novel use of anion channels, preferably Ca2+-activated anion channels (CAACs), in regulating release of neurotransmitters from neurons and/or astrocytes is provided. More specifically, CAAC activity regulators, agents for regulating neurotransmitter release comprising such CAAC activity regulators, and methods of screening agents for regulating neurotransmitter release using CAAC as a target.Type: ApplicationFiled: March 13, 2012Publication date: September 13, 2012Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Justin Changjoon LEE, Dong-Ho Woo, Hyung-Ju Park, Hye-Kyung Park
-
Publication number: 20120220642Abstract: Methods for increasing the bioabsorption of amino acids and for preventing the development of nitrate tolerances in a human or animal are disclosed. The methods include administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.Type: ApplicationFiled: May 7, 2012Publication date: August 30, 2012Applicant: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20120220643Abstract: A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.Type: ApplicationFiled: May 10, 2012Publication date: August 30, 2012Applicant: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20120214742Abstract: A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1(Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided.Type: ApplicationFiled: August 24, 2010Publication date: August 23, 2012Inventors: Changjoon Justin Lee, Soo-Jung Lee, Bo-Eun Yoon
-
Publication number: 20120214757Abstract: The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent.Type: ApplicationFiled: September 23, 2011Publication date: August 23, 2012Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Kenneth C. Anderson, Teru Hideshima, Constantine S. Mitsiades, Nicholas Mitsiades
-
Publication number: 20120208855Abstract: Provided herein is method of modulating, and in particular decreasing dihydroorotate dehydrogenase (DHODH) activity, as well as a method of treating a DHODH related disease or disorder.Type: ApplicationFiled: October 15, 2010Publication date: August 16, 2012Applicant: SANOFIInventors: Larry Raymond Mclean, Arun Subramaniam, Roy J. Vaz, Yi Li
-
Publication number: 20120208885Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: ApplicationFiled: March 30, 2012Publication date: August 16, 2012Applicant: OCERA THERAPEUTICS, INC.Inventors: Keith Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Patent number: 8242145Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: GrantFiled: February 12, 2009Date of Patent: August 14, 2012Assignee: Panmira Pharmaceuticals, LLCInventors: John Howard Hutchinson, Thomas Jonathan Seiders, Brian Andrew Stearns, Bowei Wang, Yen Pham Truong, Jeannie M. Arruda
-
Publication number: 20120201803Abstract: A process for forming a solid electrolytic capacitor and an electrolytic capacitor formed by the process. The process includes: providing an anode wherein the anode comprises a porous body and an anode wire extending from the porous body; applying a thin polymer layer onto the dielectric, and forming a dielectric on the porous body to form an anodized anode; applying a first slurry to the anodized anode to form a blocking layer wherein the first slurry comprises a first conducting polymer with an median particle size of at least 0.05 ?m forming a layer of crosslinker on the blocking layer; and applying a layer of a second conducting polymer on the layer of crosslinker.Type: ApplicationFiled: September 15, 2011Publication date: August 9, 2012Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: Shalini Sharma, James Dennen O'Neil, Reid W. von Borstel, Ramchandran Arudchandran
-
Publication number: 20120198576Abstract: Embodiments of the invention are based upon the discovery that exposure of cleavage-stage embryos to a stress inducer, e.g. heat shock or chemical, renders the exposed embryos more sensitive to a secondary treatment with a stress inducer, e.g. heat shock or chemical inducer. Accordingly, the present invention is directed to methods for making embryos, embryonic cells arising from them, and animals and plants that are sensitized to stress, e.g. physiologic or chemical stressors. Methods of screening for inducers and inhibitors of stress using, as test model systems, embryonic cells, embryos, animals, and plants that are sensitized to stress are also disclosed.Type: ApplicationFiled: July 1, 2010Publication date: August 2, 2012Applicant: BRANDEIS UNIVERSITYInventors: Lawrence J. Wangh, Cristina Hartshorn, Yanwei Jia
-
Patent number: 8232317Abstract: The present invention provides a method for stimulating hair growth, which comprises applying a composition containing a combination of a creatine compound and carnitine. The composition may further comprise 5?-AMP and NADH. Such a composition is effective in stimulating cell proliferation in the hair bulb of hair plugs.Type: GrantFiled: September 30, 2009Date of Patent: July 31, 2012Assignee: E-L Management Corp.Inventors: David C. Gan, Geoffrey Hawkins, Thomas Mammone, Richard Presti, Rose Marie Sparacio
-
Publication number: 20120184493Abstract: Described herein are topical formulations for use in the treatment or prevention of dermatological diseases, disorders, or conditions in a mammal.Type: ApplicationFiled: July 28, 2010Publication date: July 19, 2012Applicant: PANMIRA PHARMACEEUTICALS, LLCInventor: John Howard Hutchinson
-
Publication number: 20120184496Abstract: Described herein are ophthalmic pharmaceutical compositions, wherein the ophthalmic pharmaceutical compositions are in a form suitable for administration to an eye of a mammal. Ophthalmic pharmaceutical compositions disclosed herein include at least one DP2 receptor antagonist compound and are used to treat or prevent ophthalmic diseases or conditions.Type: ApplicationFiled: July 28, 2010Publication date: July 19, 2012Applicant: PANMIRA PHARMACEUTICALS, LLCInventors: John Howard Hutchinson, Thomas Jon Seiders, Nicholas Simon Stock
-
Publication number: 20120184621Abstract: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.Type: ApplicationFiled: January 3, 2012Publication date: July 19, 2012Inventor: Michael E. Silver
-
Publication number: 20120177731Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: ApplicationFiled: February 6, 2012Publication date: July 12, 2012Applicant: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Alani
-
Publication number: 20120172326Abstract: The present invention refers to a moisturizing mixture for sensitive skins, atopic dermatitis and/or Ichthyosis vulgaris containing a synergistic combination among its constituents, and cosmetic and/ pharmaceutical compositions containing said moisturizing mixture. The invention also refers to a moisturizing mixture comprising a synergistic combination between at least one cutaneous-barrier repairing agent; NMF-precursor amino acids; and at least one filagrin-synthesis stimulating agent. Cosmetic and/or pharmaceutical compositions comprising said moisturizing mixture and a physiologically acceptable carrier are also described in the present invention.Type: ApplicationFiled: November 27, 2009Publication date: July 5, 2012Applicant: Natura Cosmeticos S.A.Inventors: Patricia Da Luz Moreira, Adriano Tadeu Siqueira Jorge, Juliana Palmeira Portugal Marques, Jean Luc Gesztesi, Philip Leite Ribeiro, Sara Rocha
-
Publication number: 20120172449Abstract: Novel polyamine transport inhibitors have been synthesized and demonstrated to block the uptake of native polyamines into human cancer cells. A combination therapy of the transport inhibitor and DFMO (a drug which blocks polyamine biosynthesis) provided synergistic activity against a metastatic human colon cancer cell line. The strategy uses polyamine depletion and polyamine metabolism to generate reactive oxygen species within cells as a novel way to treat cancers. This approach may be implemented for widespread use in the treatment of diseases which rely upon polyamine transport activity for proliferation.Type: ApplicationFiled: June 21, 2010Publication date: July 5, 2012Inventors: Otto Phanstiel, Jennifer J. Archer
-
Publication number: 20120157526Abstract: Disclosed herein are methods of treating and/or preventing portal hypertension and/or restoring liver function using L-ornithine phenylacetate.Type: ApplicationFiled: June 8, 2010Publication date: June 21, 2012Applicant: UCL Business PLCInventors: Rajiv Jalan, Keith Anderson
-
Patent number: 8202853Abstract: The present invention offers an eyelid treatment kit used for convenient combination therapy for improving overall eyelid hygiene while also providing for adjunctive eyelid therapy. The eyelid treatment kit comprises low dose doxycycline hyclate tablets, a non-irritating eyelid cleansing composition, an anti-bacterial eyelid preparation and at least one pair of moist heat goggles and/or one pair of moisture chamber goggles. The eyelid treatment kit further comprises instruction sheets containing dosage and administration information on the doxycycline hyclate coupled with information on improving eyelid hygiene. The various embodiments of the eyelid treatment kit of the invention facilitate treatment of dry eyes due to infected eyelids, and proper cleansing of the eyelids to prevent recurring infections.Type: GrantFiled: December 30, 2008Date of Patent: June 19, 2012Assignee: OCuSOFT, Inc.Inventor: Nat G Adkins, Jr.
-
Patent number: 8202903Abstract: The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration.Type: GrantFiled: April 10, 2007Date of Patent: June 19, 2012Assignee: Fondazione IRCCS “CA' Granda—Ospedale Maggiore Policlinico”Inventor: Raffaella Scorza
-
Publication number: 20120149736Abstract: Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ?CH— or ?N—; W is —CH?CH— Or —CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intra-cellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-nat-ural alpha amino acid, provided that neither R2 nor R3 is hydrogen, or R2 and R3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, —C(?O)—, —S(?O)2—, —C(?O)O—, —C(?O)NR?—, —C(?5)—NR?, —C(?NH)NR? or —S(?O)2NR — wherein R? is hydrogen or optionally substituted C1—C6 alkyl; L1 is a divalent radical of formula —(Alk1)m,(Q)n(Alk2)p— wherein m, n, p, Q, Alk1 and Alk2 are as defined in the claims; X1 represents a bond; —C(?O); or —S(?O)2—; —NR4C(?O)—, —C(?O)NR4—,— NR4C(?O)NR5—, —NR4S(?O)2—, or —S(?O)2NR4— wherein R4 and R5 are independently hydrogen or optionally substituted C1Type: ApplicationFiled: February 25, 2010Publication date: June 14, 2012Applicant: Chroma Therapeutics Ltd.Inventors: Alastair David Graham Donald, David Festus Charles Moffat, Andrew James Belfield, Carl Leslie North, Stewart Andrew Wayne Jones
-
Publication number: 20120142642Abstract: The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: November 21, 2011Publication date: June 7, 2012Applicant: ALLERGAN, INC.Inventors: Wenkui K. Fang, Liming Wang, Evelyn G. Corpuz, Ken Chow, Wha-Bin Im
-
Publication number: 20120129800Abstract: The present invention concerns an agent for prevention and treatment of pityriasis. The agent according to the present invention comprises at least one transaminase inhibitor effectively inhibiting the transamination process which is of pathogenetic relevance for the disease, prevents a recurrence of the disease and which protects the human skin flora. Upon release into the environment, no resistances are induced in other fungi.Type: ApplicationFiled: January 14, 2010Publication date: May 24, 2012Applicant: Justus-Liebig-Universitat GiessenInventor: Peter Mayser
-
Publication number: 20120128735Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: ApplicationFiled: November 21, 2011Publication date: May 24, 2012Applicant: DEPOMED, INC.Inventors: Bret BERNER, Sui Yuen Eddie HOU
-
Publication number: 20120129939Abstract: Disclosed herein are methods for treating a disease involving ?-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce ?-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce ?-synucleic aggregation; or (3) a compound which inhibits ?-synucleic aggregation in an amount effective to reduce ?-synucleic aggregation. Also disclosed are methods for reducing the amount of ?-synucleic aggregation in a brain cell using (1) a compound which reduces the amount of polyamines in an amount effective to reduce ?-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce ?-synucleic aggregation; or (3) a compound which inhibits ?-synucleic aggregation in an amount effective to reduce ?-synucleic aggregation. Disclosed herein are also compounds which can be used in the above described methods.Type: ApplicationFiled: March 1, 2010Publication date: May 24, 2012Inventors: Scott A. Small, Nicole Lewandowski, Donald W. Landry, Shi-Xiang Deng